SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Drugmax, Inc. (Nasdaq: DMAX) - B2B pharmaceuticals

No earlier versions found for this Subject.


Return to Drugmax, Inc. (Nasdaq: DMAX) - B2B pharmaceuticals
 
DrugMax.com (known as Nutriceuticals.com until the name change is completed) is a new entrant in B2B e-commerce. The company's goal is to become the premier online business-to-business trade exchange for manufacturers, distributors, wholesalers, and retailers in the Pharmaceutical, Over-the-Counter, Health and Beauty, and Natural Product industries. The company's website (http://www.DrugMax.com) will feature auctions, a wholesale marketplace, classified ads, and reverse auctions.

Including its pending acquisition of Becan Distributors, Inc., Nutriceuticals.com's pro forma sales for the year ended March 31, 1999 were $31 million. Sales for the year ending March 31, 2000 are expected to double to $62 million. And for the following year, sales could double once again.

Nutriceuticals.com is about to complete a stock offering which will raise approximately $12 million and give it a Nasdaq listing under the symbol DMAX. The offering price will likely be $10 per share, and it is expected to start trading on Nasdaq on Monday, November 22.

At a price of $10, the company would have a market cap of approximately $60 million. Compared to the billion dollar market caps of B2B stocks such as Chemdex and VerticalNet, Nutriceuticals.com certainly has significant upside potential.

While DMAX is new to B2B e-commerce, it will already have significant sales due to the Becan acquisition. Also because of Becan, the company will have a customer base that can use its B2B services. For many other startup companies, gaining its first customers is a major problem.

At its current price, I think DMAX looks like an interesting investment. I'd like to hear what other people think...

Jeff